Project
Diagnosis and risk stratification of patients with cardiomyopathy
- Project term
06/2023 - 06/2025
- Granted budget
€ 40,000
- Research resource used
Resource liquid samples/image data
- Keywords
cardiomyopathy, biomarker, iPSC-cardiomyocytes
- Principal Investigator
-
Antje Ebert, Wolfram-Hubertus Zimmermann, Benjamin Meder (Department for Cardiology and Pneumology, University Medical Center Goettingen; Institute of Pharmacology and Toxicology, University Medical Center Goettingen; Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg)
To improve diagnosis and risk stratification of patients with cardiomyopathy, this project assesses secretome biomarker profiles via proteomic analysis methods.
The DZHK biospecimen from patients with dilated or hypertrophic cardiomyopathy (DCM/HCM) enable the validation of common biomarkers from DCM/HCM patients in human iPSC-derived cardiomyocytes from patients with DCM/HCM mutations. These studies may support the development of future therapeutic and diagnostic approaches. A better understanding of the molecular mechanisms in cardiomyopathy via profiling of secreted biomarkers could facilitate future diagnostics and therapies for patients with cardiomyopathy.
Publications
There are no publications available yet.